Literature DB >> 21938493

The history and future of probenecid.

Nathan Robbins1, Sheryl E Koch, Michael Tranter, Jack Rubinstein.   

Abstract

Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21938493     DOI: 10.1007/s12012-011-9145-8

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  40 in total

1.  Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis.

Authors:  Nadine Hainz; Sandra Wolf; Thomas Tschernig; Carola Meier
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

2.  Novel role of transient receptor potential vanilloid 2 in the regulation of cardiac performance.

Authors:  Jack Rubinstein; Valerie M Lasko; Sheryl E Koch; Vivek P Singh; Vinicius Carreira; Nathan Robbins; Amit R Patel; Min Jiang; Philip Bidwell; Evangelia G Kranias; W Keith Jones; John N Lorenz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-12-06       Impact factor: 4.733

Review 3.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

4.  Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Authors:  Christopher C Coss; Amanda Jones; James T Dalton
Journal:  Invest New Drugs       Date:  2016-04-22       Impact factor: 3.850

Review 5.  Lesinurad: A Review in Hyperuricaemia of Gout.

Authors:  Emma D Deeks
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  Towards longitudinal mapping of extracellular pH in gliomas.

Authors:  Yuegao Huang; Daniel Coman; Peter Herman; Jyotsna U Rao; Samuel Maritim; Fahmeed Hyder
Journal:  NMR Biomed       Date:  2016-07-29       Impact factor: 4.044

8.  Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.

Authors:  Fabio Arturo Iannotti; Ester Pagano; Aniello Schiano Moriello; Filomena Grazia Alvino; Nicolina Cristina Sorrentino; Luca D'Orsi; Elisabetta Gazzerro; Raffaele Capasso; Elvira De Leonibus; Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

9.  Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model.

Authors:  Sheryl E Koch; Michael Tranter; Nathan Robbins; Kristin Luther; Umesh Singh; Min Jiang; Xiaoping Ren; Trisha Tee; Leah Smith; Priyanka Varma; W Keith Jones; Jack Rubinstein
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-12-14       Impact factor: 2.457

Review 10.  What do we know about the transient receptor potential vanilloid 2 (TRPV2) ion channel?

Authors:  Alex Perálvarez-Marín; Pau Doñate-Macian; Rachelle Gaudet
Journal:  FEBS J       Date:  2013-05-28       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.